Email Alert RSS
Volume 14 Issue 4
Jul.  2023
Turn off MathJax
Article Contents
Abstract
References
WEN Xuejun, ZHOU Wuhao, GUO Zhide, ZHANG Xianzhong. Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 766-773. DOI: 10.12290/xhyxzz.2023-0155
Citation: WEN Xuejun, ZHOU Wuhao, GUO Zhide, ZHANG Xianzhong. Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 766-773. DOI: 10.12290/xhyxzz.2023-0155
shu

Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy

  • 1.

    State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, Fujian 361102, China

  • 2.

    Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Institute of Clinical Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Funds: 

National Natural Science Foundation of China 81901805

National Natural Science Foundation of China 21976150

National Natural Science Foundation of China 21906135

More Information
  • Corresponding author:

    GUO Zhide, E-mail: gzd666888@xmu.edu.cn

    ZHANG Xianzhong, E-mail: zhangxzh@hotmail.com

  • Received Date: March 27, 2023
  • Accepted Date: July 02, 2023
  • Available Online: July 25, 2023
  • Issue Publish Date: July 29, 2023
    Graphical Abstract
    • Abstract
  •   Objective  To investigate the effect of 99mTc-labeled RGD peptide (99mTc-RGD) on regulating the tumor immune microenvironment and enhancing the anti-tumor effect of immunotherapy when combined with anti-programmed death-ligand 1 (PD-L1) antibody.
      Methods  The expression of PD-L1 on tumor cells was detected by flow cytometry, and the distribution of 99mTc-RGD in MC38 tumor mice was evaluated using single photon emission computed tomography(SPECT) imaging. The combination therapy was performed to monitor the anti-tumor effect.
      Results  The expression of PD-L1 on CT26, MC38, 4T1 and B16F10 tumor cells was upregulated after being induced by 99mTc-RGD, and there was a statistical significance between 99mTc-RGD treated and untreated groups. Subsequently, SPECT imaging was performed by injecting 99mTc-RGD into MC38 tumor-bearing mice, and significant tumor uptake was observed. Based on this, the combination of 99mTc-RGD and anti-PD-L1 antibody in MC38 tumor mice was studied, and the results showed that different doses and time windows had significant effects on the efficacy of the combination therapy. The combination of 18.5 MBq or 37 MBq 99mTc-RGD with an anti-PD-L1 antibody led to the best therapeutic effect at 4 h intervals.
      Conclusions  99mTc-RGD could induce the upregulation of tumor PD-L1 expression, and when combined with an anti-PD-L1 antibody, it could enhance the anti-tumor effect.
    • FullText(HTML)
    • References (17)
  • [1]
    Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca Cancer J Clin, 2021, 71: 209-249. DOI: 10.3322/caac.21660
    [2]
    Das S, Al-Toubah T, El-Haddad G, et al. Lu-177-DOTA-TATE for the treatment of gastroenteropancreatic neuroendocrine tumors[J]. Expert Rev Gastroent, 2019, 13: 1023-1031. DOI: 10.1080/17474124.2019.1685381
    [3]
    Hennrich U, Eder M. [Lu-177] Lu-PSMA-617 (Pluvicto (TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer[J]. Pharmaceuticals, 2022, 15: 1292. DOI: 10.3390/ph15101292
    [4]
    Wen XJ, Zeng XY, Shing CR, et al. PD-L1-Targeted Radionuclide Therapy Combined with alpha PD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect[J]. Mol Pharmaceut, 2022, 19: 3612-3622. DOI: 10.1021/acs.molpharmaceut.2c00281
    [5]
    Wen XJ, Zeng XY, Shi CR, et al. Optimum Combination of Radiopharmaceuticals-Based Targeting-Triggering-Therapy Effect and PD-L1 Blockade Immunotherapy[J]. Adv Therap, 2023, 6: 22001
    [6]
    Gutfilen B, Al Souza S, Valentini G. Copper-64: a real theranostic agent[J]. Drug Des Dev Ther, 2018, 12: 3235-3245. DOI: 10.2147/DDDT.S170879
    [7]
    Wen XJ, Zeng XY, Liu J, et al. Synergism of Cu-64-Labeled RGD with Anti-PD-L1 Immunotherapy for the Long-Acting Antitumor Effect[J]. Bioconjugate Chem, 2022, 33: 2170-2179. DOI: 10.1021/acs.bioconjchem.2c00408
    [8]
    Wen XJ, Shi CR, Zeng XY, et al. A Paradigm of Cancer Immunotherapy Based on 2-[18F] FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect[J]. Clin Cancer Res, 2022, 28: 2923-2937. DOI: 10.1158/1078-0432.CCR-22-0159
    [9]
    Niu G, Chen XY. Why Integrin as a Primary Target for Imaging and Therapy[J]. Theranostics, 2011, 1: 30-47. DOI: 10.7150/thno/v01p0030
    [10]
    Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis[J]. Nat Rev Cancer, 2018, 18: 532-547.
    [11]
    Zhou Y, Kim YS, Chakraborty S, et al. 99mTc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin αvβ3 Expression[J]. Mol Imaging, 2011, 10: 386-397.
    [12]
    Zhou Y, Kim YS, Lu X, et al. Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties[J]. Bioconjug Chem, 2012, 23: 586-595. DOI: 10.1021/bc200631g
    [13]
    Baskar R, Lee K A, Yeo R, et al. Cancer and Radiation Therapy: Current Advances and Future Directions[J]. Int J Med Sci, 2012, 9: 193-199. DOI: 10.7150/ijms.3635
    [14]
    Norouzi S, Gorgi Valokala M, Mosaffa F, et al. Crosstalk in cancer resistance and metastasis[J]. Crit Rev Oncol Hematol, 2018, 132: 145-153. DOI: 10.1016/j.critrevonc.2018.09.017
    [15]
    Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells[J]. Nat Rev Cancer, 2022, 22: 190. DOI: 10.1038/s41568-022-00445-6
    [16]
    Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy[J]. Science, 2020, 367: eaax0182. DOI: 10.1126/science.aax0182
    [17]
    de Miguel M, Calvo E. Clinical Challenges of Immune Checkpoint Inhibitors[J]. Cancer Cell, 2020, 38: 326-333. DOI: 10.1016/j.ccell.2020.07.004
    • Related Articles

  • Cited by

    Periodical cited type(8)

    1. 卯润，蔡毅媛，杨薇，刘志国，令狐浪，陈佳佳，梁梦娇，黄列玉，刘思源，徐东. 实施性研究利益相关方偏好评估——优劣尺度法的应用. 协和医学杂志. 2025(01): 224-234 . 本站查看
    2. 徐东，蔡毅媛，陈江芸. 实施科学的前世今生（下篇）——理论、范式和特点. 协和医学杂志. 2024(03): 686-693 . 本站查看
    3. 宋再伟，赵荣生，陈耀龙，徐东. 基于高质量循证用药指南制定与实施的临床药学“实践-研究一体化”模式构建与实践. 中国临床药学杂志. 2024(06): 401-407 .
    4. 何娜，吴紫阳，翟所迪. 药物安全性证据生态体系：从发现药物不良反应信号到优化风险管理. 药物不良反应杂志. 2024(10): 584-587 .
    5. 高鉴国，王凤华，邵金华. 高校心理健康服务提供者能力提升项目的实施研究. 临沂大学学报. 2024(06): 95-107 .
    6. 卯润，蔡毅媛，杨程茗，彭井兰，宁芷晴，刘思源，徐东. 实施性研究利益相关方偏好评估. 协和医学杂志. 2024(06): 1447-1455 . 本站查看
    7. 蔡见文，朱涛，李为民，李培艺. 基于NASSS框架的人工智能在真实围术期世界中实施性研究的系统评价. 中国循证医学杂志. 2024(11): 1284-1293 .
    8. 石慧峰，陈晓燕，赵扬玉. 现阶段中国孕产妇死亡的影响因素和应对策略. 中国实用妇科与产科杂志. 2024(12): 1153-1156 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1934) PDF downloads (84) Cited by(8)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close